NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 327 filers reported holding NOVOCURE LTD in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $312,099 | -86.6% | 19,325 | -65.6% | 0.00% | -90.0% |
Q2 2023 | $2,333,794 | -30.9% | 56,236 | +0.1% | 0.01% | -33.3% |
Q1 2023 | $3,379,507 | -12.2% | 56,194 | +4.4% | 0.02% | -21.1% |
Q4 2022 | $3,851,008 | -11.7% | 53,837 | -6.2% | 0.02% | -13.6% |
Q3 2022 | $4,359,000 | +18.9% | 57,382 | +8.8% | 0.02% | +29.4% |
Q2 2022 | $3,665,000 | -16.4% | 52,736 | -0.4% | 0.02% | 0.0% |
Q1 2022 | $4,385,000 | +5.0% | 52,936 | -0.8% | 0.02% | +13.3% |
Q4 2021 | $4,175,000 | -34.4% | 53,355 | -2.6% | 0.02% | -37.5% |
Q3 2021 | $6,363,000 | -46.1% | 54,776 | +3.0% | 0.02% | -45.5% |
Q2 2021 | $11,795,000 | +71.2% | 53,178 | +2.0% | 0.04% | +63.0% |
Q1 2021 | $6,891,000 | -23.5% | 52,139 | -2.2% | 0.03% | -27.0% |
Q4 2020 | $9,009,000 | +528.2% | 53,293 | +313.7% | 0.04% | +428.6% |
Q3 2020 | $1,434,000 | +87.7% | 12,883 | 0.0% | 0.01% | +75.0% |
Q2 2020 | $764,000 | -12.0% | 12,883 | 0.0% | 0.00% | -20.0% |
Q1 2020 | $868,000 | +194.2% | 12,883 | +268.6% | 0.01% | +400.0% |
Q4 2019 | $295,000 | – | 3,495 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Invus Financial Advisors, LLC | 350,884 | $77,833,000 | 15.51% |
HARTLINE INVESTMENT CORP/ | 302,194 | $67,033,000 | 8.47% |
Darsana Capital Partners LP | 700,000 | $155,274,000 | 4.42% |
MORGAN JESS S & CO INC | 23,775 | $5,274,000 | 3.47% |
Soleus Capital Management, L.P. | 98,975 | $21,955,000 | 3.38% |
Montanaro Asset Management Ltd | 116,650 | $25,875,000 | 3.26% |
Taylor Frigon Capital Management LLC | 31,035 | $6,884,000 | 2.15% |
Rhenman & Partners Asset Management AB | 120,000 | $26,618,000 | 1.81% |
COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $2,218,000 | 1.33% |
Derbend Asset Management | 5,789 | $1,284,000 | 1.20% |